Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06372821 · ClinicalTrials.gov registry record · Phase 1

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

A Phase 1 study of Alzheimer Disease and Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), sponsored by University College, London.

Recruiting
Registry status
Phase 1
Development phase
10
Enrollment target
2
Study locations

NCT06372821 is a Phase 1 study of Alzheimer Disease and Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder) that is actively recruiting participants, run by University College, London. The registered enrollment target is 10 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06372821, a Phase 1 study of Alzheimer Disease and Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), is actively recruiting participants, sponsored by University College, London.

RECRUITING
Registry status
Phase 1
Development phase
10 participants
Enrollment target
2
Study locations

Study Summary

This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve cells, which interfere with how the nerve cells work, and eventually die. This is what causes the symptoms of dementia. It is thought that NIO752 reduces production of tau.

Conditions Studied

Alzheimer Disease Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder) Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder) Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)

Interventions

  • OTHER Placebo
  • DRUG NIO752

Study Locations (2)

Missouri

  • Washington University in St. Louis - St Louis

Other

  • University College London Hospitals NHS Foundation Trust - London

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2024-11-18
Est. Completion 2026-07
Phase Phase 1

Sponsor

University College, London

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06372821

The ClinicalTrials.gov registry entry for NCT06372821 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The listed sponsor is University College, London, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06372821 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Missouri, Other.

Frequently Asked Questions

What is clinical trial NCT06372821 about?

NCT06372821 is a clinical study titled "A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK". This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve cel...

What is the current status of trial NCT06372821?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-11-18. Estimated completion is 2026-07.

What conditions does trial NCT06372821 study?

This clinical trial studies the following conditions: Alzheimer Disease, Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder).

What interventions are being tested in trial NCT06372821?

The interventions under investigation include: Placebo (OTHER), NIO752 (DRUG).

Who is sponsoring clinical trial NCT06372821?

This trial is sponsored by University College, London, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06372821 being conducted?

This trial has 2 study locations across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder)

All registered trials for this condition

Missouri

All trials with a study site in Missouri

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.